Asia HDAC inhibitors
繁體中文As of 2026-11-01, Drugnews tracks 5 Asian programs in HDAC inhibitors across China and Taiwan; the most advanced is Tucidinostat / chidamide / Epidaza from Chipscreen Biosciences (Approved).
Companies
- Anbogen Therapeutics
- Chengdu Zenitar Biomedical Technology
- Chipscreen Biosciences
- Syndax; Taizhou EOC Pharma / Edding Genor (China)
- Xynomic Pharmaceuticals
Assets
| Company | Country | Code | Asset | Mechanism | Stage | Indication | Partner | Deal terms | Sources |
|---|---|---|---|---|---|---|---|---|---|
| Anbogen Therapeutics | Taiwan | ABT-301 | ABT-301 / MPT0E028 | Class I and IIb | Phase 1b/2 (registry phases 1/2), recruiting; pMMR/non-MSI-H advanced/metastatic CRC + tislelizumab + bevacizumab (NCT07244705). | — | — | — | 2026-10-05 2025-11-24 |
| Chengdu Zenitar Biomedical Technology | China | Purinostat mesylate | Purinostat mesylate | Classes I and IIb-selective | Phase 3, recruiting: purinostat mesylate vs selinexor in relapsed/refractory DLBCL (NCT07011056). | — | — | — | 2025-06-23 2025-09-19 |
| Chipscreen Biosciences | China | Tucidinostat | Tucidinostat / chidamide / Epidaza | Class I (HDAC1/2/3) and IIb (HDAC10)-selective | China: PTCL (2014), HR+/HER2− advanced breast cancer with endocrine therapy (2019), untreated MYC/BCL2-positive DLBCL + R-CHOP (2024). Japan: ATL and PTCL (2021). Taiwan: breast cancer + exemestane (2023). | — | — | — | 2024-04-30 2026-04-23 2011-11-12 |
| Syndax; Taizhou EOC Pharma / Edding Genor (China) | China | Entinostat | Entinostat / SNDX-275 / MS-275 | Class I-selective | China approved (April 2024): HR+/HER2− locally advanced or metastatic breast cancer progressing after endocrine therapy, with an aromatase inhibitor. Syndax has deprioritised development. | — | — | — | 2026-02-26 2026-04-15 |
| Xynomic Pharmaceuticals | China | Abexinostat | Abexinostat / PCI-24781 | Pan-HDAC (HDAC1/2/3/6/10) | Phase 3 RENAVIV, recruiting: abexinostat + pazopanib in advanced/metastatic RCC (NCT03592472). | — | — | — | 2019-07-11 2026 2025-04-13 |
No matches. Clear the search to show all assets.
Outbound licensing deals
No source-linked licensing records are present in this input snapshot.
FAQ
How many Asian HDAC inhibitors programs are tracked?
The November 1, 2026 table contains 5 programs in 5 company groups, across China and Taiwan.
Which program is the most advanced?
Tucidinostat / chidamide / Epidaza from Chipscreen Biosciences is listed as Approved. This is the highest source-dated stage in this table, shared by 2 programs; stages and dates are shown for each asset.
What does this page cover?
The table covers HDAC programs with Asian company or regional development involvement. Company geography does not establish molecular origin. Stages refer to the sourced indications and territories.
Which Taiwanese programs are included?
ABT-301 (Phase 1b/2).
How many Asian outbound licensing events are listed?
The table contains 0 published licensing events. Upfront payments and potential total values are separate; this snapshot does not establish that no deals exist.